



FY18 RESULTS

GAAP
NET REVENUE

\$15.8 BILLION

PERFORMANCE NET
INCOME PER SHARE¹

\$16.69

GAAP Loss Per Share \$15.26

CORE BUSINESS GREW 8.3%
ON STRENGTH IN **MEDICAL
AESTHETICS AND CENTRAL
NERVOUS SYSTEM²**

R&D PIPELINE ACHIEVED
**POSITIVE RESULTS IN 6 KEY
LATE STAGE PROGRAMS** INCLUDING
CARIPRAZINE AND UBROGEPANT

**REDUCED DEBT BY \$6.2
BILLION** AND EXECUTED
**\$2.7 BILLION IN SHARE
REPURCHASE PROGRAM**

GAAP REVENUE DRIVEN BY GROWTH IN TOP PROMOTED PRODUCTS:



¹ Non-GAAP financial measure. Please refer to the GAAP to non-GAAP tables in January 29, 2019 Press Release on Allergan.com for a reconciliation of our non-GAAP results.

² Core Business = Promoted Brands & Brands with Ongoing Exclusivity + Other Product Revenue. Growth percentage vs. FY 2017, excluding FX.